SCHEMBL1237689

SCHEMBL1237689

O=C(O)c1ccc(CO)c(CO)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 3/20 0.53
TSHR P16473 3/20 0.48
TP53 P04637 1/20 0.48
PKM P14618 1/20 0.47
CA12 O43570 4/20 0.46
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
CA6 P23280 4/20 0.46
CA9 Q16790 4/20 0.46
CA4 P22748 3/20 0.46
CA7 P43166 3/20 0.46
CA14 Q9ULX7 3/20 0.46
KDM4E B2RXH2 2/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
PTGS2 P35354 1/20 0.46
ALDH1A1 P00352 4/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29654186 1.00 ACE2 (0.53) ACE2TSHRTP53PKMCA12
SCHEMBL17058903 0.90 ACE2 (0.53) ACE2TSHRTP53PKMCA12
SCHEMBL17625007 0.88 ACE2 (0.51) ACE2TSHRTP53PKMCA12
SCHEMBL8984332 0.85 ACE2 (0.49) ACE2TSHRTP53PKMKDM4E
SCHEMBL1408523 0.84 KDM4E (0.50) ACE2TSHRTP53PKMCA12
SCHEMBL10548309 0.84 PKM (0.48) ACE2TSHRPKML3MBTL1MAPT
SCHEMBL8482490 0.83 ACE2 (0.50) ACE2TSHRTP53PKMCA12
SCHEMBL8534552 0.83 CA12 (0.59) ACE2TSHRTP53PKMCA12
SCHEMBL12018296 0.83 CPT1B (0.45) ACE2TSHRTP53PKMPTGS2
SCHEMBL4109854 0.83 PKM (0.69) ACE2TSHRTP53PKMCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4245830-B1 LUBRICANT BASE OIL KAO CORP (JP) 2025-09-10 EP disclosed
US-12098341-B2 Lubricant base oil KAO CORPORATION (JP) 2024-09-24 US disclosed
CN-118255663-A Extraction method and application of 3, 4-dihydroxymethyl benzoate 大理大学 2024-06-28 CN disclosed
CN-118255663-A Extraction method and application of 3, 4-dihydroxymethyl benzoate 大理大学 2024-06-28 CN disclosed
US-20230383208-A1 LUBRICANT BASE OIL KAO CORPORATION (JP) 2023-11-30 US disclosed
EP-4245830-A1 LUBRICANT BASE OIL Kao Corporation (JP) 2023-09-20 EP disclosed
EP-2565245-B1 Moisture-proof material NITTO DENKO CORP (JP) 2018-07-25 EP disclosed
US-9963427-B2 Dithiol mucolytic agents PARION SCIENCES, INC. (US) 2018-05-08 US disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
EP-2666836-A2 Moisture-proof material Nitto Denko Corporation (JP) 2013-11-27 EP disclosed
EP-2565245-A2 Moisture-proof material NITTO DENKO CORPORATION (JP) 2013-03-06 EP disclosed
US-20130052461-A1 MOISTURE-PROOF MATERIAL NITTO DENKO CORPORATION (JP) 2013-02-28 US disclosed
US-20120308640-A1 AMPHIPHILIC JANUS-DENDRIMERS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-12-06 US disclosed
WO-2011017500-A1 AMPHIPHILIC JANUS-DENDRIMERS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2011-02-10 WO disclosed
CN-101146780-A New 3-aryl-1,2-benzisoxazole compounds are heat shock protein 90 inhibitors, useful to treat solid or liquid cancer, preferably cancers resistant to cytotoxic agents AVENTIS PHARMA SA (FR) 2008-03-19 CN disclosed
EP-0714390-B1 INDOLE DERIVATIVES AS 5-ALPHA-REDUCTASE-1-INHIBITORS PFIZER LTD (GB) 2000-01-12 EP disclosed
US-5912357-A Indole derivatives as 5-α-reductase-1-inhibitors PFIZER INC (US) 1999-06-15 US disclosed
EP-0714390-A1 INDOLE DERIVATIVES AS 5-ALPHA-REDUCTASE-1-INHIBITORS Pfizer Limited (GB) 1996-06-05 EP disclosed
WO-1995005375-A1 INDOLE DERIVATIVES AS 5-ALPHA-REDUCTASE-1-INHIBITORS PFIZER LIMITED (GB) 1995-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120308640-A1 AMPHIPHILIC JANUS-DENDRIMERS OR10J3, H1-10, CXCR3 ACE2 3215/4885TSHR 852/4885TP53 4016/4885
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS MAVS, SARS1, ZC3HAV1 ACE2 117/4885TSHR 4424/4885TP53 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.